<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">46581249X</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180323112120.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">170327e19900401xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1007/BF03190192</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)springer-10.1007/BF03190192</subfield>
  </datafield>
  <datafield tag="100" ind1="1" ind2=" ">
   <subfield code="a">Sanders</subfield>
   <subfield code="D">L.</subfield>
   <subfield code="u">Syntex Research, 3401 Hillview Ave, 94303, Palo Alto, CA, USA</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="245" ind1="1" ind2="0">
   <subfield code="a">Drug delivery systems and routes of administration of peptide and protein drugs</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[L. Sanders]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">Summary: The unique requirements of peptides and proteins in designing delivery systems, and the unprecedented recent growth in the field, has driven a great deal of research into novel means of drug delivery. The search for approaches that provide formulations that are stable, bioavailable, readily manufacturable, and acceptable to the patient, has led to major advances in development of nasal and controlled release technology. The field of parenteral solution technology has also seen some new demands made of it, and what was formerly a conventional area of formulation technology has made scientific advances to meet the needs of these compounds. At the same time, strides are being made in fundamental research in areas including oral delivery, transdermal delivery, and pulsatile and ‘on demand' delivery of peptides and proteins.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">Springer-Verlag, 1990</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Peptide delivery</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">protein delivery</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">controlled release</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">systemic delivery</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">protein formulation</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">delivery routes</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">European Journal of Drug Metabolism and Pharmacokinetics</subfield>
   <subfield code="d">Springer-Verlag</subfield>
   <subfield code="g">15/2(1990-04-01), 95-102</subfield>
   <subfield code="x">0378-7966</subfield>
   <subfield code="q">15:2&lt;95</subfield>
   <subfield code="1">1990</subfield>
   <subfield code="2">15</subfield>
   <subfield code="o">13318</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1007/BF03190192</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1007/BF03190192</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">100</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Sanders</subfield>
   <subfield code="D">L.</subfield>
   <subfield code="u">Syntex Research, 3401 Hillview Ave, 94303, Palo Alto, CA, USA</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">European Journal of Drug Metabolism and Pharmacokinetics</subfield>
   <subfield code="d">Springer-Verlag</subfield>
   <subfield code="g">15/2(1990-04-01), 95-102</subfield>
   <subfield code="x">0378-7966</subfield>
   <subfield code="q">15:2&lt;95</subfield>
   <subfield code="1">1990</subfield>
   <subfield code="2">15</subfield>
   <subfield code="o">13318</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">Springer special CC-BY-NC licence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-springer</subfield>
  </datafield>
 </record>
</collection>
